scholarly journals FREQUENCY OF DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS AMONG CONVENTIONALLY HEALTHY POPULATION OF RUSSIAN FEDERATION

2017 ◽  
pp. 99-106
Author(s):  
N. V. Soboleva ◽  
A. A. Karlsen ◽  
T. V. Kozhanova ◽  
V. S. Kichatova ◽  
V. V. Klushkina ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Russian Federation ◽  
Age Groups ◽  
Moscow Region ◽  
Healthy Population ◽  
High Morbidity ◽  
Age Cohorts ◽  
Screening Programs ◽  
Total Prevalence

Aim. Determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among conditionally healthy population of Russian Federation. Materials and methods. Sera samples obtained from conditionally healthy population of the Russian Federation from 5 geographically distant regions with different levels of morbidity for hepatitis C were studied: Sverdlovsk, Rostov, Moscow regions, Tyva and Sakha (Yakutia) Republics. 4764 samples were studied in total obtained from individuals of 10 age groups: younger than 1, 1 - 4, 5 - 9, 10 - 14,15 - 19, 20 - 29, 30 - 39, 40 - 49,50 - 59, olderthan 60 years. Anti-HCV were determined by commercial ELISA. Results. The total prevalence of anti-HCV in 5 regions of Russian Federation was 2.6% (126/4764). The highest frequency of detection of anti-HCV was detected in Tyva and Yakutia Republics and was 3.3%, in other regions this parameter varied from 1,7 (Moscow region) to 3% in Sverdlovsk region. Peak parameters of anti-HCV detection among population in various regions were connected with various age groups: olderthan 60 years in Tyva and Yakutia Republics (11 and 9.9%, respectively), 40 - 49 in Moscow region (6.2%), 1 - 4 and 30 - 39 years in Sverdlovsk region (5.9 and 4.9%, respectively) and 20 - 39 in Rostov region (3.9%). Conclusion. Results of anti-HCV detection in various age cohorts of conditionally healthy population of Russian Federation give evidence regarding high morbidity with HCV of almost all the age groups in the interval from 20 to older than 60 years. Age cohorts were detected in each of the studied regions for which inclusion into regional screening programs is feasible.

scholarly journals The prevalence of the hepatitis C virus among the conditionally healthy population of the Russian Federation

2017 ◽  
Vol 9 (2) ◽  
pp. 56-64 ◽  
Author(s):  
N. V. Soboleva ◽  
A. A. Karlsen ◽  
T. V. Kozhanova ◽  
V. S. Kichatova ◽  
V. V. Klushkina ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Russian Federation ◽  
Healthy Population ◽  
The Russian Federation

scholarly journals Prevalence of Hepatitis C Virus in the Population of Albania for the Period 2007-2010

2014 ◽  
Vol 2 (3) ◽  
pp. 525-528 ◽  
Author(s):  
Hysaj Vila Brunilda ◽  
Shundi Lila ◽  
Abazaj Erjona ◽  
Bino Silva ◽  
Rexha Tefta
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Age Groups ◽  
Viral Disease ◽  
Hcv Infection ◽  
University Hospital ◽  
P Value ◽  
Hcv Rna ◽  
Significant Difference ◽  
Males And Females

BACKGROUND: Hepatitis C is a blood-borne, infectious, viral disease that is caused by a hepatotropic virus called Hepatitis C virus (HCV).AIM: The aim of this study is to determine the prevalence of active HCV infection (HCV–RNA) in the cases that were anti-HCV positive.MATERIAL AND METHODS: Plasma of 301 high-risk for HCV infection consecutive from University Hospital Centre “Mother Theresa” Tirana-Albania, during January 2007 to December 2010 was included in this study. To identify the presence of HCV RNA, the samples were examined by Cobas Amplicor HCV test (qualitative method).RESULTS: From 301 samples analyzed in total, 214 of them resulted positive for the presence of HCV-RNA's, corresponding to a prevalence of 71.1%, with 95% CI interval [65.8 - 75.9] for value of χ2 = 52.7 p value <0.0001. Divide by the sex 56% were males and 44% females, with statistically significant difference between them for value χ2 =4306 p value=0.0380. Among the age groups the highest prevalence was observed in the age groups > 25 years with a significant difference with other age groups for p value <0.001.CONCLUSION: Among tested samples, 71.1 % were confirmed to be positive for HCV –RNA infections. The prevalence of male was highest compared to female. For males and females infected the prevalence was highest in the age group of > 25 years.

scholarly journals Promising Anti-Hepatitis C Virus Compounds from Natural Resources

2016 ◽  
Vol 11 (8) ◽  
pp. 1934578X1601100 ◽  
Author(s):  
Tutik Sri Wahyuni ◽  
Chie Aoki Utsubo ◽  
Hak Hotta
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Natural Resources ◽  
Antiviral Agents ◽  
High Morbidity ◽  
Current Standard ◽  
Treatment Regimens ◽  
Medicinal Plant Extracts ◽  
Ns3 Protease

Hepatitis C virus (HCV) infection is a major worldwide problem, which involves approximately 170 million people. High morbidity of patients is caused by chronic infection, which leads to liver cirrhosis, hepatocellular carcinoma and other HCV-related diseases. The sustained virological response (SVR) has been markedly improved to be >90% by the current standard interferon (IFN)-free treatment regimens with a combination of direct-acting antiviral agents (DAAs) targeting the viral NS3 protease, NS5A multi-function protein and NS5B RNA-dependent RNA polymerase, compared with 50–70% of SVR rates achieved by the previous standard IFN-based treatment regimens with or without an NS3 protease inhibitor. However, the emergence of DAA-resistant HCV strains and the limited access to the DAAs due to their high cost could be major concerns. Also, the long-term prognosis of patients treated with DAAs, such as the possible development of hepatocellular carcinoma, still needs to be further evaluated. Natural resources are considered to be good candidates to develop anti-HCV agents. Here, we summarize anti-HCV compounds obtained from natural resources, including medicinal plant extracts, their isolated compounds and some of their derivatives that possess high antiviral potency against HCV.

scholarly journals Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections

2016 ◽  
Vol 54 (8) ◽  
pp. 2023-2030 ◽  
Author(s):  
Kelly E. Coller ◽  
Michael G. Berg ◽  
Matthew Frankel ◽  
Kenn Forberg ◽  
Rita Surani ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Nonstructural Protein ◽  
The Other ◽  
The Novel ◽  
Gb Virus C ◽  
E2 Glycoprotein ◽  
Total Prevalence ◽  
Disease Associations ◽  
Virus C

A novel blood-borne human pegivirus (HPgV), HPgV-2, was recently identified in hepatitis C virus (HCV)-infected individuals and individuals who had received multiple transfusions. Robust serological assays capable of detecting antibodies in HPgV-2-infected individuals are needed to establish global seroprevalence rates and potential disease associations. The two objectives of this study were to determine the utility of mammalian cell-expressed HPgV-2 E2 glycoprotein or bacterium-expressed nonstructural protein 4AB (NS4AB) in detecting past or present infections and to compare the total prevalence (antibody and RNA positive) of HPgV-2 with that of the other human pegivirus, HPgV-1 (GB virus C [GBV-C]). HPgV-2 E2 antibodies were detected in 13 (92.86%) of 14 HPgV-2-viremic cases, and NS4AB antibodies were detected in 8 (57.14%) of 14 cases. The HPgV-2 seroprevalence was significantly higher (P< 0.0001) among HCV-infected individuals (3.31% [24 of 726 samples]) than among non-HCV-infected individuals (0.30% [4 of 1,348 samples]). Of 31 anti-E2-positive samples, 22 had supplemental supporting data; 12 samples were HPgV-2 RNA positive and 10 nonviremic samples were antibody positive for peptides or NS4AB. The total prevalence of HPgV-1 (35.00%) was significantly higher than that of HPgV-2 (1.33%) in all populations tested (P< 0.0001). For HPgV-1, codetection of antibodies to E2 and RNA was infrequent (5.88%). In contrast, antibodies to E2 were detected in most HPgV-2-viremic individuals (92.86%), as is observed among individuals chronically infected with HCV, most of whom are antibody positive for HCV E2. Our studies indicate that HPgV-2 circulates with HCV and displays a profile similar to the serological profile of HCV-infected persons, although the pathogenicity of this virus has yet to be established.

scholarly journals Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek

2015 ◽  
Vol 156 (21) ◽  
pp. 841-848
Author(s):  
Gábor Horváth ◽  
Tünde Halász ◽  
Mihály Makara ◽  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Virus Hepatitis ◽  
Direct Acting Antivirals ◽  
Screening Programs ◽  
Viral Response ◽  
Direct Acting

Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal. Orv. Hetil., 2015, 156(21), 841–848.

scholarly journals Dasabuvir inhibits human norovirus infection in human intestinal enteroids

2021 ◽  
Author(s):  
Tsuyoshi Hayashi ◽  
Kosuke Murakami ◽  
Junki Hirano ◽  
Yoshiki Fujii ◽  
Yoko Yamaoka ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Severe Acute Respiratory Syndrome ◽  
Culture System ◽  
Age Groups ◽  
Viral Gastroenteritis ◽  
Compound Library ◽  
Human Norovirus ◽  
Antiviral Compound ◽  
Acute Viral Gastroenteritis

Human noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to treat HuNoV infection are available. In this study, with a human intestinal enteroid (HIE) culture system where HuNoVs are able to replicate reproducibly, we screened an antiviral compound library to identify compound(s) showing anti-HuNoV activity. Dasabuvir, which has been developed as an anti-hepatitis C virus agent, was found to inhibit HuNoV infection in HIEs at micromolar concentrations. Dasabuvir also inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human A rotavirus (RVA) infection in HIEs. To our knowledge, this is the first study to screen an antiviral compound library for HuNoV using HIEs and we successfully identified dasabuvir as a novel anti-HuNoV inhibitor that warrants further investigation.

scholarly journals Frequency Distribution of Hepatitis C Virus Genotypes with Reference to Age and Sex in Various Districts of Khyber Pakhtunkhwa, Pakistan

2021 ◽  
pp. 83-88
Author(s):  
Bakht Biland ◽  
Mohsina Haq ◽  
Sardar Muhammad ◽  
Mohsan Subhani ◽  
Syed Gardezi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Age Groups ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Female Population ◽  
Khyber Pakhtunkhwa ◽  
Significant Difference ◽  
Age And Sex ◽  
Genotype 3A

Background: Pakistan has the second highest prevalence of hepatitis C in the world after Egypt. Viral hepatitis is a leading cause of morbidity and mortality in Pakistan and, worryingly, reinfection rates are also on the rise. This cross-sectional study was aimed at finding the most common genotypes of hepatitis C in terms of age and sex in a Pakistani cohort. Materials and methods: The authors collected blood samples from 1,260 patients with diagnosed hepatitis C visiting a primary teaching hospital affiliated with Peshawar Medical College, Pakistan, from different districts of Khyber Pakhtunkhwa, Pakistan, between January 2017 and April 2019. Hepatitis C virus RNA was quantified by real-time polymerase chain reaction and genotyping was then performed. Results: The authors found that genotype 3a was the most prevalent type followed by 1a, mixed, and 3b, respectively. Genotypes 2a and 1b were the least prevalent in Khyber Pakhtunkhwa. The most common genotype was 3a, observed in 75.87% of cases. The most common mixed genotype was 3a+1a, observed in 39 cases (3.10%); it had a prevalence of 3.49% in females compared with 2.70% in males. Overall, the most common age group affected by hepatitis C virus was 41–50 years (31.35%), followed by the 51–60 years group (24.45%). Infection rate was comparatively low in other age groups. A significant difference was observed in the prevalence of genotype 3a and 2a among different districts. Conclusion: The authors concluded that genotype 3a was the most prevalent genotype and it was observed more frequently in the female population, with a median age of 45 years.

scholarly journals Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: results from three cross-sectional studies (2005, 2009, 2018)

2020 ◽  
pp. sextrans-2020-054464
Author(s):  
Charlotte Lanièce Delaunay ◽  
Joseph Cox ◽  
Marina Klein ◽  
Gilles Lambert ◽  
Daniel Grace ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sexual Risk ◽  
Temporal Trends ◽  
Age Groups ◽  
Hiv Status ◽  
Cross Sectional ◽  
Factors Associated ◽  
Sex With Men

ObjectivesTo eliminate the hepatitis C virus (HCV) by 2030, Canada must adopt a microelimination approach targeting priority populations, including gay, bisexual and other men who have sex with men (MSM). Accurately describing HCV prevalence and risk factors locally is essential to design appropriate prevention and treatment interventions. We aimed to estimate temporal trends in HCV seroprevalence between 2005 and 2018 among Montréal MSM, and to identify socioeconomic, behavioural and biological factors associated with HCV exposure among this population.MethodsWe used data from three cross-sectional surveys conducted among Montréal MSM in 2005 (n=1795), 2009 (n=1258) and 2018 (n=1086). To ensure comparability of seroprevalence estimates across time, we standardised the 2005 and 2009 time-location samples to the 2018 respondent-driven sample. Time trends overall and stratified by HIV status, history of injection drug use (IDU) and age were examined. Modified Poisson regression analyses with generalised estimating equations were used to identify factors associated with HCV seropositivity pooling all surveys.ResultsStandardised HCV seroprevalence among all MSM remained stable from 7% (95% CI 3% to 10%) in 2005, to 8% (95% CI 1% to 9%) in 2009 and 8% (95% CI 4% to 11%) in 2018. This apparent stability hides diverging temporal trends in seroprevalence between age groups, with a decrease among MSM <30 years old and an increase among MSM aged ≥45 years old. Lifetime IDU was the strongest predictor of HCV seropositivity, and no association was found between HCV seroprevalence and sexual risk factors studied (condomless anal sex with men of serodiscordant/unknown HIV status, number of sexual partners, group sex).ConclusionsHCV seroprevalence remained stable among Montréal MSM between 2005 and 2018. Unlike other settings where HCV infection was strongly associated with sexual risk factors among MSM, IDU was the pre-eminent risk factor for HCV seropositivity. Understanding the intersection of IDU contexts, practices and populations is essential to prevent HCV transmission among MSM.

scholarly journals Seroprevalência do Anticorpo do Vírus na Hepatite A em Viajantes Portugueses: Um Novo Paradigma

2017 ◽  
Vol 30 (7-8) ◽  
pp. 534
Author(s):  
Sónia Rocha ◽  
Sandra Tejo ◽  
Eugénia Ferreira ◽  
Luís Trindade ◽  
Eduardo Rabadão ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Age Groups ◽  
Sub Saharan Africa ◽  
Immunodeficiency Virus

Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.

Sign in / Sign up

Export Citation Format

Share Document